Hsa_circ_0044907 promotes acute myeloid leukemia progression through upregulating oncogene KIT via sequestering miR-186-5p

References

• Pasquer H, Tostain M, Kaci N, et al. Descriptive and functional genomics in acute myeloid leukemia (AML): paving the road for a cure. Cancers (Basel). 2021;13(4):748.
   PubMed Web of Science ®Google Scholar
• Almond LM, Charalampakis M, Ford SJ, et al. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263–267.
   PubMed Web of Science ®Google Scholar
• Westhus J, Noppeney R, Dührsen U, et al. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2019;60(4):1014–1022.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Marcucci G. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine. Chin Clin Oncol. 2019;8(S1):S25.
   PubMedGoogle Scholar
• Xu S, Zhang M, Fang X, et al. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia. J Hematol Oncol. 2021;14(1):193.
   PubMed Web of Science ®Google Scholar
• Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Garzon R. Clinical applications of MicroRNAs in acute myeloid leukemia: A mini-review. Front Oncol. 2021;11:679022.
   PubMed Web of Science ®Google Scholar
• Wang Q, Feng T, Xu J, et al. Mitochondrial inner membrane protein, Mic60/mitofilin in mammalian organ protection. J Cell Physiol. 2019;234(4):3383–3393.
   PubMed Web of Science ®Google Scholar
• Butrym A, Rybka J, Baczyńska D, et al. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res. 2015;34(1):68.
   PubMedGoogle Scholar
• de Leeuw DC, Verhagen HJ, Denkers F, et al. MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia. Leukemia. 2016;30(3):742–746.
   PubMed Web of Science ®Google Scholar
• Shang Q, Yang Z, Jia R, et al. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18(1):6.
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555–565.
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442.
   PubMed Web of Science ®Google Scholar
• de Acha O P, Rossi M, Gorospe M. Circular RNAs in blood malignancies. Front Mol Biosci. 2020;7:109.
   PubMed Web of Science ®Google Scholar
• Yi YY, Yi J, Zhu X, et al. Circular RNA of vimentin expression as a valuable predictor for acute myeloid leukemia development and prognosis. J Cell Physiol. 2019;234(4):3711–3719.
   PubMed Web of Science ®Google Scholar
• Lin L, Wang Y, Bian S, et al. A circular RNA derived from PLXNB2 as a valuable predictor of the prognosis of patients with acute myeloid leukaemia. J Transl Med. 2021;19(1):123.
   PubMed Web of Science ®Google Scholar
• Wang X, Jin P. CircSPI1 acts as an oncogene in acute myeloid leukemia through antagonizing SPI1 and interacting with microRNAs. Cell Death Dis. 2021;12(4):297.
   PubMed Web of Science ®Google Scholar
• Ding Y, Dong Y, Lu H, et al. Circular RNA profile of acute myeloid leukaemia indicates circular RNA annexin A2 as a potential biomarker and therapeutic target for acute myeloid leukaemia. Am J Transl Res. 2020;12(5):1683–1699.
   PubMed Web of Science ®Google Scholar
• Alanazi B, Munje CR, Rastogi N, et al. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia. 2020;34(2):427–440.
   PubMed Web of Science ®Google Scholar
• Johnson DC, Taabazuing CY, Okondo MC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24(8):1151–1156.
   PubMed Web of Science ®Google Scholar
• Hall IF, Climent M, Quintavalle M, et al. Circ_Lrp6, a circular RNA enriched in vascular smooth muscle cells, acts as a sponge regulating miRNA-145 function. Circ Res. 2019;124(4):498–510.
   PubMed Web of Science ®Google Scholar
• Dong S, Wang R, Wang H, et al. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 2019;38(1):110.
   PubMedGoogle Scholar
• Ouyang Y, Li Y, Huang Y, et al. CircRNA circPDSS1 promotes the gastric cancer progression by sponging miR-186-5p and modulating NEK2. J Cell Physiol. 2019;234(7):10458–10469.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang W, Mao J, et al. miR-186-5p functions as a tumor suppressor in human osteosarcoma by targeting FOXK1. Cell Physiol Biochem. 2019;52(3):553–564.
   PubMedGoogle Scholar
• Bi Y, Mao Y, Su Z, et al. HOXB-AS1 accelerates the tumorigenesis of glioblastoma via modulation of HOBX2 and HOBX3 at transcriptional and posttranscriptional levels. J Cell Physiol. 2021;236(1):93–106.
   PubMed Web of Science ®Google Scholar
• Zhang TJ, Wang YX, Yang DQ, et al. Down-Regulation of miR-186 correlates with poor survival in de novo acute myeloid leukemia. Clin Lab. 2016;62(1-2):113–120.
   PubMed Web of Science ®Google Scholar
• Lin J, Ma JC, Yang J, et al. Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression. Oncogene. 2018;37(18):2432–2443.
   PubMed Web of Science ®Google Scholar
• Wen XM, Zhang TJ, Ma JC, et al. Establishment and molecular characterization of decitabine-resistant K562 cells. J Cell Mol Med. 2019;23(5):3317–3324.
   PubMed Web of Science ®Google Scholar
• Roskoski R., The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacol Res. 2018;133:35-52.
   PubMed Web of Science ®Google Scholar
• Bougherara H, Subra F, Crépin R, et al. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res. 2009;7(9):1525–1533.
   PubMed Web of Science ®Google Scholar
• Ashman LK, Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs. 2013;22(1):103–115.
   PubMed Web of Science ®Google Scholar
• Hu Y, Dong X, Chu G, et al. miR-137 downregulates c-kit expression in acute myeloid leukemia. Leuk Res. 2017;57:72–77.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang L, Xu G. Silencing of long noncoding RNA TUG1 inhibits viability and promotes apoptosis of acute myeloid leukemia cells by targeting microRNA-221-3p/KIT axis. Clin Hemorheol Microcirc. 2020;76(3):425-437.
   PubMed Web of Science ®Google Scholar
• Gao XN, Lin J, Gao L, et al. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res. 2011;35(9):1226–1232.
   PubMed Web of Science ®Google Scholar
• Malani D, Yadav B, Kumar A, et al. KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia. 2020;34(10):2780–2784.
   PubMed Web of Science ®Google Scholar